Oceanside-based SeraCare Life Sciences, Inc. announced Nov. 29 that it plans to acquire certain assets of Serologicals Corp.
SeraCare will acquire diagnostic manufacturing facilities in Milford, Mass. , near an existing SeraCare facility , as well as the product lines of a Serologicals subsidiary called Celliance.
SeraCare will pay $3.7 million in cash and assume certain liabilities. Information on the liabilities was not immediately available.
SeraCare trades on the Nasdaq as SRLS. Its stock was trading at $21.35 at 11 a.m. Nov. 29.
The deal is expected to close in January.
, Brad Graves